{"id":558211,"date":"2021-08-17T16:54:05","date_gmt":"2021-08-17T16:54:05","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=558211"},"modified":"2021-08-17T16:54:05","modified_gmt":"2021-08-17T16:54:05","slug":"psoriasis-pipeline-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-developments-and-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/psoriasis-pipeline-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-developments-and-companies-by-delveinsight_558211.html","title":{"rendered":"Psoriasis Pipeline: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, Developments and Companies by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1629182555.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Psoriasis Pipeline: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, Developments and Companies by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1629182555.jpeg\" alt=\"Psoriasis Pipeline: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, Developments and Companies by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Psoriasis Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psoriasis-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Psoriasis<\/a><\/strong>&nbsp;is a condition that directly affects the human skin. The condition is a long-term disease that currently has very few or no treatment options. The severity of the illness and inadequate treatment methods will lead to a high emphasis on early detection and treatment of the disease worldwide. The increasing research and development activities and increased investments in these activities will create several growth opportunities for the companies working in the market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s&nbsp;<strong>&#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psoriasis-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Psoriasis Pipeline<\/a> Insight, 2021,&#8221;&nbsp;<\/strong>report provides comprehensive insights about&nbsp;<strong>80+ companies and 80+ pipeline drugs<\/strong>&nbsp;in the Psoriasis pipeline landscape. The report covers the pipeline drug profiles, including clinical &amp; non-clinical stage products.&nbsp;<strong>Psoriasis Pipeline Insight<\/strong>&nbsp;also covers the therapeutics assessment by stage, product type, route of administration, &amp; molecule type. The report further highlights the inactive pipeline products in this space.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Psoriasis companies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Mylan<\/li>\n<li>Biocad<\/li>\n<li>Bristol-Myers Squibb<\/li>\n<li>Celltrion<\/li>\n<li>Coherus BioSciences<\/li>\n<li>Janssen Pharmaceuticals<\/li>\n<li>Can-Fite Biopharma<\/li>\n<li>Arcutis Biotherapeutics<\/li>\n<li>Amgen<\/li>\n<li>Iltoo Pharma<\/li>\n<li>GlaxoSmithKline<\/li>\n<li>Galectin Therapeutics<\/li>\n<li>Evelo Biosciences<\/li>\n<li>Galderma<\/li>\n<li>BioMimetix JV<\/li>\n<li>Menlo Therapeutics Inc.<\/li>\n<li>Aristea Therapeutics<\/li>\n<li>UNION Therapeutics<\/li>\n<li>MetrioPharm<\/li>\n<li>Sienna Biopharmaceuticals<\/li>\n<li>And Many More<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/psoriasis-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/psoriasis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Psoriasis Symptoms include red patches, itchiness, rashes, and irritation. The increasing medical activities associated with the condition and the growing emphasis on the development of efficient treatment options will emerge in favor of the growth of the overall psoriasis treatment market in the foreseeable future.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Psoriasis Types<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Plaque psoriasis<\/li>\n<li>Guttate psoriasis<\/li>\n<li>Flexural (inverse) psoriasis<\/li>\n<li>Erythroderma<\/li>\n<li>Generalized pustular psoriasis<\/li>\n<li>Palmoplantar pustulosis<\/li>\n<li>Psoriatic nail disease<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/psoriasis-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Psoriasis Therapies<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>CT-P43<\/li>\n<li>EDP1815<\/li>\n<li>AZD0284<\/li>\n<li>Bimekizumab<\/li>\n<li>Mirikizumab<\/li>\n<li>And Many More<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of&nbsp;Psoriasis Pipeline Drug Insight<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage:&nbsp;<\/strong>Global&nbsp;<\/li>\n<li><strong>Major Players: 80+ Key Players<\/strong><\/li>\n<li><strong>Prominent Players:&nbsp;<\/strong>Abbvie, Jannsen, Dermavant Sciences, UCB, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Arcutis Biotherapeutics, Amgen, Mylan, Clover Biopharmaceuticals, Sienna Biopharmaceuticals, Fresenius Kabi, Celltrion, Bristol Myers Squibb, LEO Pharma, Crescita Therapeutics, GlaxoSmithKline, Coherus BioSciences, Fujifilm Kyowa Kirin Biologics, Zydus Cadilla, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Biocad, Torrent Pharmaceuticals, Alvotech, Maruho Co., Ltd., Arcutis Biotherapeutics, Inc., Eli Lilly and Company, Can-Fite Biopharma, MetrioPharm, Provectus Pharmaceuticals, Sienna Biopharmaceuticals, and many others.&nbsp;&nbsp;<\/li>\n<li><strong>Key Drugs Profiles: 80+ Products<\/strong><\/li>\n<li><strong>Phases:&nbsp;&nbsp;<\/strong><\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<ul>\n<li>Psoriasis Therapies Late-stage (Phase III)&nbsp;&nbsp;<\/li>\n<li>Psoriasis Therapies (Phase II)<\/li>\n<li>Psoriasis Therapies (Phase I)&nbsp;<\/li>\n<li>Psoriasis Therapies Pre-clinical stage and Discovery candidates&nbsp;<\/li>\n<li>Discontinued and Inactive candidates&nbsp;<\/li>\n<\/ul>\n<li><strong>Therapies:<\/strong><\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Cell Therapy<\/li>\n<li>Monoclonal Antibodies<\/li>\n<li>Protein<\/li>\n<li>Small Molecule<\/li>\n<li>Intramuscular<\/li>\n<li>Intravenous<\/li>\n<li>Oral<\/li>\n<li>Parental<\/li>\n<li>Topical<\/li>\n<li>Transdermal&nbsp;<\/li>\n<li>Immunosuppressants<\/li>\n<li>Tumour necrosis factor-alpha inhibitors<\/li>\n<li>Aryl hydrocarbon receptor agonists<\/li>\n<li>IL17F protein inhibitors<\/li>\n<li>Interleukin-23 subunit p19 inhibitors<\/li>\n<li>Interleukin 12 inhibitors<\/li>\n<li>Interleukin 23 inhibitors<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li><strong>Route of Administration:<\/strong><\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li><strong>Mechanism of Action:<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/psoriasis-pipeline-insight?utm_source=Icrowd&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/psoriasis-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Psoriasis: Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Psoriasis &ndash; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">Psoriasis Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">CT-P43: Celltrion<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">EDP1815: Evelo Biosciences<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">AZD0284: AstraZeneca<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Preclinical)<\/p>\n<p style=\"text-align: justify;\">AZD0284: AstraZeneca<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">Psoriasis Key Companies<\/p>\n<p style=\"text-align: justify;\">Psoriasis Key Products<\/p>\n<p style=\"text-align: justify;\">Psoriasis- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Psoriasis- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Psoriasis- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Psoriasis Analyst Views<\/p>\n<p style=\"text-align: justify;\">Psoriasis Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Delveinsight :&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.<\/p>\n<p style=\"text-align: justify;\">Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform&nbsp;<strong>PharmDelve<\/strong>.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=psoriasis-pipeline-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-developments-and-companies-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/psoriasis-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/psoriasis-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/psoriasis-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=psoriasis-pipeline-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-developments-and-companies-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Psoriasis Pipeline Psoriasis&nbsp;is a condition that directly affects the human skin. The condition is a long-term disease that currently has very few or no treatment options. The severity of the illness and inadequate treatment methods will lead to a high &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/psoriasis-pipeline-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-developments-and-companies-by-delveinsight_558211.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,406,423,413],"tags":[],"class_list":["post-558211","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/558211","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=558211"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/558211\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=558211"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=558211"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=558211"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}